- Home
- SGMO vs TARA Comparison
SGMO vs TARA Comparison
Compare SGMO & TARA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGMO
- TARA
- Stock Information
- Founded
- SGMO 1995
- TARA N/A
- Country
- SGMO United States
- TARA United States
- Employees
- SGMO N/A
- TARA N/A
- Industry
- SGMO Biotechnology: Biological Products (No Diagnostic Substances)
- TARA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SGMO Health Care
- TARA Health Care
- Exchange
- SGMO Nasdaq
- TARA Nasdaq
- Market Cap
- SGMO 122.8M
- TARA 118.1M
- IPO Year
- SGMO 2000
- TARA N/A
- Fundamental
- Price
- SGMO $0.58
- TARA $3.03
- Analyst Decision
- SGMO Buy
- TARA Strong Buy
- Analyst Count
- SGMO 6
- TARA 7
- Target Price
- SGMO $4.50
- TARA $20.67
- AVG Volume (30 Days)
- SGMO 7.8M
- TARA 214.2K
- Earning Date
- SGMO 08-07-2025
- TARA 08-11-2025
- Dividend Yield
- SGMO N/A
- TARA N/A
- EPS Growth
- SGMO N/A
- TARA N/A
- EPS
- SGMO N/A
- TARA N/A
- Revenue
- SGMO $81,706,000.00
- TARA N/A
- Revenue This Year
- SGMO $1.29
- TARA N/A
- Revenue Next Year
- SGMO $1.60
- TARA N/A
- P/E Ratio
- SGMO N/A
- TARA N/A
- Revenue Growth
- SGMO 565.52
- TARA N/A
- 52 Week Low
- SGMO $0.41
- TARA $1.60
- 52 Week High
- SGMO $3.18
- TARA $10.48
- Technical
- Relative Strength Index (RSI)
- SGMO 58.57
- TARA 44.29
- Support Level
- SGMO $0.50
- TARA $3.06
- Resistance Level
- SGMO $0.58
- TARA $3.33
- Average True Range (ATR)
- SGMO 0.05
- TARA 0.17
- MACD
- SGMO 0.00
- TARA -0.01
- Stochastic Oscillator
- SGMO 84.21
- TARA 4.65
About SGMO Sangamo Therapeutics Inc.
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.
About TARA Protara Therapeutics Inc.
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).